Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30

IPSTE S a

22249 Routine ophthalmologic screening for detection of asymptomatic CMV
retinitis
David Wohl*; S. Pedersen, USA
22250 Detection of GB Virus-C/Hepatitis G Virus (GBV-C/HGV) among
homosexual male HIV patients: Risk factor analysis of infection
Martin Wdchtler*; G. Frosner; H. Nitschko; G. Miiller; M. Karwat;
C.H.R. Emmingger; D. Eichenlaub, Germany
22251 The role of cytomegalovirus (CMV)-Antigenemia as predictive and
follow up marker of CMV retinitis in AIDS patients
Yoshihiko Hoshino*; T. Nakamura; Y. Nagata; Y. Fujino; M. Mochizuki;
A. Iwamoto, Japan
22252 Influence of HIV protease inhibitors on hepatitis C viral (HCV) load and
serum alamine aminotransferase (s-alt) in patients with HIV and HCV
coinfection
Louis Bernard*; P. Matsiota-Bernard; F. Bani-Sadr; D. Mathez;
P. De Truchis; C Perronne, France
22253 Cytomegalovirus encephalitis in eight patients with AIDS: Clinical and
laboratory findings
Yann Gerard*; Daouda Sissoko; L. Bocket; C Fontier; L. Maulin; A. Dewilde;
P. Wattre; Y. Mouton, France
22254 An open trial of intravenous ganciclovir three times or five times a week
as CMV retinitis maintenance therapy
Eduardo Sprinz*; J. Peter; R. IlgenFritz; M. W. Jeffman, Brazil
22255 The correlation between HIV and Hepatitis C co-infection: A case control
study
Margaret Hoffman-Terry*; A.K. Gupta; T.E. Wasser, USA
22256 Clinical practice of CMV-retinitis treatment with cidofovir in
experienced patients: Results of the German cidofovir study group
Jiirgen Rockstroh*; H. Jdger; K. Schliefer;J. Kolberg;J. Poppinger;
E. Laenroth-May; A. Ulmer, Germany
22257 Low CMV disease progression after initiation of protease-inhibitors
therapy: A long term follow-up in 30 patients
Christine Chandemerle*; Christoihe Michon; H. Moussalatti; M. Saillour;
T. Hanslik; D. Zucman; F. Tremolieres; G. Force, France
22258 Risk of CMV disease in the ERA of protease inhibitors
E. Martinez*;J. Mallolas;J.M. Mird;A. Guelar; F. Garcia;J.M. Gatell, Spain
22259 Coinfection with hepatitis B and HIV in pregnant women in Bobo
Dioulasso, Burkina Faso
Blami Dao*; B. Nacro; H. Dahourou; N. Meda; P. Van de Perre; M. Cartoux,
Burkina Faso
22260 Containment of CMV retinitis under HAART despite termination of antiCMV therapy
RaviK. Walli*; U. Schaller;J.R. Bogner; A. Scheider; A.J. Mueller; V. Ulauss;
F.D. Goebel, Germany
22261 Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients.
Prevalence and prognostic value
Thomas Benfield, Denmark
22262 Cytomegalovirus (CMV) in the cerebrospinal fluid (CSF) of AIDS patients
without CMV disease
Nina K. Regevik*; M. Shilpa; G. Jimenez;J.R. Middleton; S. Nilsson;
N. Rosner; P. Sen, USA

22263 Seroprevalence of hepatitis C antibody and hepatitis B surface
antigenemia in a large urban HIV clinic
Samuel T. Merrick*; K.A. Sepkowitz; B.A. Boyle;J.L. Jacobs, USA
22264 Prevalence and genotypes of hepatitis G virus and hepatitis C virus
among HIV-infected patients: Evidence of HGV sexual transmission
MiguelAngel Marinez; A. lbaiez; M. Gimenez-Bancons; A. Tajahuerce;
C Tural;J.M. Sanchez-Tapias;J.C Saiz, Spain
22265 Relationship between the detection of plasma cytomegalovirus (CMV)
DNA and CMV retinitis in AIDS patients
Charlene Bush*; Richard Donovan; J. Carlsen; N.B. Mateo; N.P. Markowitz;
R.M. Donovan, USA
22266 Quantitation of JC virus in CSFAND urine prognostic value of CSF JC viral
load in patients with progressive multifocalleukoencephalopathy
Yassine Taoufik*;A. Karaterki; J. Gasnault; M.P. Ferey; M.G. De Goer;
J.F. Delfraissy; E. Dussaix, France
22267 Induction treatment of CMV:A comparison between single and twice
daily dosing of ganciclovir
Jorge Luis Gazineo*; E.C. Joao Filho; A.L. Senna; A. Silva; M.L. Fernandes;
M.L.L. Giordani; M.L.S. Cruz, Brazil
22268 Long-lasting remission of CMV-retinitis without specific CMVmaintenance therapy after initiation of HAART in 4 AIDS patients
Thomas Lutz*; T. Stark; P. Gute; V. Miller; H. Guempel; S. Staszewski;
E. Helm, Germany, Germany
22269 Impact of indinavir (Protease inhibitor) on HCV viral load in patients
coinfected with HCV-HIV
Odile Bouchard*; G. Gavazzi; P. Leclercq; P. Morand; A. Bosseray;
J.M. Seignevrin, France
22270 Oral ganciclovir (GCV) for maintenance therapy of cytomegalovirus
(CMV) retinitis. Experience from the European compassionate use
programme
Marianne Walker*; M. Popescu, Switzerland
22271 Nonprogression of CMV retinitis in AIDS patients on highly active
antirretroviral treatment (HAART)
Gabriela Ortega-Larrocea*; Juan Sierra-Madero; D. Carranza-Salazar,
Mexico
22272 HLA class I antigens and class II alleles in Brazilian AIDS patients with
cytomegalovirus retinitis (CMV-R)
Maria De Lourdes Veronese Rodrigues*;J.F.C. De Castro Figueiredo;
E.A. Mabtum; N.H.S. Deghaide; N. Vieira De Souza; E. Romdo; E.A. Donadi,
Brazil
22273 Extensive optic disc neovascularization in a patient with
cytomegalovirus retinitis
Daneil Colombero*; E. Teicher; S. Lupo; M.C. Novo; P. Barbieri, Argentina
22274 HBS antigen in children with suspicion of HIV-infection
Boubacar Nacro*; B. Dao; H. Dahourou; P. Bonkoungou; FR. Tall,
Burkina Faso
22275 Effect of highly active antiretroviral treatment (HAART) in patients with
AIDS-associated Kaposi's sarcoma (KS)
Sara Santambrogio*; A.L. Ridolfo; N. Tosca; M. Galli; C. Parravicini;
M. Corbellino, Italy
22276 Anti-tumor Activity of Oral 9-cis-Retinoic Acid in AIDS related Kaposi's

sarcoma: AIDS Malignancy Consortium Study 002
Steven Miles*; B. Dezube; J. Lee; L. Kaplan;J. Groopman; W. Saville;
D. Scadden, USA

88

12th World AIDS Conference Geneva